AstraZeneca Results Presentation Deck
Emerging markets
Diverse and solid growth
$m
3,000
2,500
2,000
1,500
1,000
500
Q1 2018
Q2 2018
Q3 2018
Emerging markets +21%
EM excl. China +36%; China +11%
Q4 2018
Q1 2019
Q2 2019
Q3 2019
China EM excluding China
Total revenue at actual exchange rates; changes
at CER and for H1 2021, unless stated otherwise.
18
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Q4 2020
Q1 2021
Q2 2021
Performance driven by new medicines
up 29% (35% of total revenue; $1.8bn¹)
Oncology +6%: Tagrisso (+10%) ; March 2021 NRDL inclusion
New CVRM +28%: Forxiga (+77%) ; roxadustat ($92m)
Respiratory & Immunology +10%: Pulmicort ($405m, +2%);
Symbicort ($306m, +2%)
Diversified growth: AP² +4%, MEA³ +73%, LA4¹ +48%, Russia
+6%; benefit from vaccine shipments
2021 China patient access: major NRDL inclusion Tagrisso 1L
but VBP impact to now Pulmicort, Brilinta, Nexium and legacy
Revenue anticipated to continue growing ahead of the
long-term ambition of mid to high single-digit growth
Total revenue at actual exchange rates; changes at CER and for H1 2021, unless stated otherwise.
1. Total revenue at CER 2. Asia Pacific 3. Middle East, Africa and other 4. Latin America.
3View entire presentation